Rep. John Lively has proposed a cost-saving and drug-management measure that would allow the Oregon Health Authority to deny new drugs that have been approved by the FDA in the past six months, while PhRMA is fighting to strip the provision from legislation that passed the House unanimously. The measure does not impact CCOs, which can determine the suitability of most drugs.
Apr 30, 2015